Good morning, We received a GPC feasibility request due 3/28. Please review<https://redcap.gpcnetwork.org/redcap_v6.11.5/DataEntry/index.php?pid=16&id=48&page=gpc_droc_oversight_request> and submit the counts as soon as possible.
Once your site has approved the request, please upload the counts to: Request#48_Barohn_Feasibility_ALS_Meds<https://redcap.gpcnetwork.org/surveys/?s=EYYD7AWMXP> The details of the request are attached and below. Four queries are posted on Babel: Shared\1. Feasibility Requests\Request#48 Research Title: Riluzole (Rilutek©) and Edaravone (Radicava©) for ALS (R&R): Implementation and Outcomes Inclusion Criteria: * G12.21 or 335.20 twice with the diagnosis code (Date Range: 01/01/2015-12/31/2018) * Seen Twice In Neurology (Date Range: 01/01/2015-12/31/2018) Exclude: * Deceased Questions: 1. Total Number of Patients Meeting Criteria Above 2. Of the patients above, how many are on Rilutek or Riluzole from 01/01/2015-12-31/2018 3. Of the patients above, how many are on edavarone or Radicava from 01/01/2015-12-31/2018 4. Of the patients above, how many are on both from 01/01/2015-12-31/2018 Please let me know if you have any questions! Thank you, Maren Lowrance Clinical Informatics Coordinator Frontiers Informatics Navigator 913-588-7688
Searchcriteria.docx
Description: Searchcriteria.docx
_______________________________________________ Gpc-dev mailing list Gpc-dev@listserv.kumc.edu http://listserv.kumc.edu/mailman/listinfo/gpc-dev
